ORLANDO, Fla. — Naim Alkhouri, MD, of the Digestive Disease Institute at the Cleveland Clinic, provides his perspective on interferon-free therapies for hepatitis C at Digestive Disease Week 2013.
Alkhouri cites encouraging data from trials of sofosbuvir and ribavirin in patients with HCV genotypes 2 and 3, in which high SVR rates were observed after 12 to 16 weeks of treatment. He suggests that interferon-free treatments may become available in the near future, including compounds for use in patients with HCV genotype 1.
Alkhouri cites encouraging data from trials of sofosbuvir and ribavirin in patients with HCV genotypes 2 and 3, in which high SVR rates were observed after 12 to 16 weeks of treatment. He suggests that interferon-free treatments may become available in the near future, including compounds for use in patients with HCV genotype 1.
http://www.healio.com/infectious-disease/hepatitis-resource-center-2013/naim-alkhouri-md-discusses-interferon-free-regimens-for-hcv
No comments:
Post a Comment